Lung cancer genotype-based therapy and predictive biomarkers: present and future.

doi:10.5858/arpa.2012-0508-RA

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Lung cancer genotype-based therapy and predictive biomarkers: present and future.

Archives of pathology & laboratory medicine - 1 Dec 2012

Cagle Philip T, Allen Timothy Craig

Abstract excerpt

CONTEXT: The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. OBJECTIVE: To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. DATA SOURCES: Data were obtained...

Topics

Antineoplastic Agents
Biomarkers
Combined Modality Therapy
Drug Resistance, Neoplasm
Genotype
Humans
Lung Neoplasms
Molecular Targeted Therapy
Mutation
Pathology, Molecular
Precision Medicine
Professional Role
Prognosis
Workforce

Source

Open in PubMed

Identifiers

PMID: 23194040
DOI: 10.5858/arpa.2012-0508-RA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics